1. Introduction

Consumer Genomics Data Exclusivity refers to the legal and commercial control exercised over genetic information collected from individuals through consumer DNA-testing services, genetic ancestry platforms, health-risk prediction applications, and direct-to-consumer genomic testing companies.

Consumer genomics companies collect highly sensitive personal information, including:

DNA sequences and genetic markers.

Ancestry and ethnic-origin information.

Hereditary disease predispositions.

Genetic relationships and family connections.

Pharmacogenomic information concerning responses to medicines.

Biological information that may reveal information about relatives who have never used the service.

Data exclusivity arises when a company claims exclusive rights to access, process, analyse, commercialise, license, or otherwise control genomic datasets.

The central legal question is whether a company can obtain commercial exclusivity over genetic information supplied by consumers, particularly when that information is personal, sensitive, potentially identifiable, and relevant to public health and scientific research.

In the Moroccan context, this issue must be examined through personal-data protection, constitutional privacy, contractual obligations, consumer protection, intellectual-property law, and competition law.

An important distinction: Exclusivity over a company's legitimately developed database, software, or analytical methods is not the same as ownership of an individual's genetic identity. A commercial contract cannot automatically convert a person's biological information into the company's unrestricted property.

2. Legal Framework in Morocco

A. Constitution of Morocco, 2011

The Moroccan Constitution provides important foundations for genomic privacy.

Article 24 protects private life and personal communications.

Article 22 protects physical and moral integrity.

Article 31 establishes public responsibilities concerning access to healthcare and other essential services.

These constitutional principles support protection against unjustified collection, disclosure, and commercial exploitation of personal genetic information.

B. Law No. 09-08 on Personal Data Protection

Law No. 09-08 is particularly important because genomic information can identify an individual or reveal sensitive information about that individual.

Its principal relevance includes:

Lawfulness of personal-data processing.

Purpose limitation.

Proportionality of collection.

Data accuracy.

Security and confidentiality.

Individual rights concerning personal information.

Conditions governing disclosure and transfers of personal data.

The National Commission for the Control of Personal Data Protection (CNDP) has an important supervisory role.

Genomic companies cannot assume that a consumer's initial consent authorises every future commercial use of their DNA information.

C. Consumer Protection Law No. 31-08

This legislation is relevant where genomic testing companies sell services directly to consumers.

It raises questions concerning:

Transparency of testing services.

Unfair contractual conditions.

Misleading commercial representations.

Disclosure of data-sharing practices.

Consumer consent and contractual fairness.

Remedies for misleading or harmful commercial conduct.

D. Intellectual Property Law No. 17-97

Moroccan intellectual-property legislation may protect qualifying databases, software, inventions, and commercial innovations.

However, intellectual-property protection must be distinguished from ownership of naturally occurring human genetic information.

A company may protect its qualifying analytical technology or database structure without acquiring unlimited proprietary rights over an individual's genome.

E. Competition Law No. 104-12

Competition Law No. 104-12 is relevant where a genomics company uses exclusive data control to prevent competitors from entering the market.

Potential concerns include:

Exclusionary licensing arrangements.

Refusal to provide access to commercially essential datasets.

Restrictive agreements with hospitals or laboratories.

Anti-competitive mergers involving genomic databases.

Exclusive partnerships with healthcare institutions.

Leveraging control over genetic information into related diagnostic markets.

3. Meaning and Forms of Consumer Genomics Data Exclusivity

A. Exclusive control over genetic databases

A genomics company may collect DNA information from millions of customers and create a proprietary database.

It may claim exclusive commercial control over:

Genetic sequencing results.

Ancestry databases.

Disease-associated genetic patterns.

Population-level genetic statistics.

Genetic matching systems.

The legal problem arises when database exclusivity prevents consumers, researchers, or competing laboratories from obtaining legitimate access to information.

B. Exclusive licensing arrangements

A genomics company may enter into agreements with pharmaceutical companies, universities, hospitals, or biotechnology businesses.

Such agreements may provide exclusive access to particular datasets.

For example, a pharmaceutical company may obtain exclusive rights to analyse a dataset containing genetic information relevant to developing a particular medicine.

These arrangements require examination of consent, purpose limitation, confidentiality, and competition effects.

C. Exclusive commercial exploitation

Companies may monetise genomic information through:

Pharmaceutical research partnerships.

Drug-discovery programmes.

Genetic risk prediction services.

Personalised medicine.

Population-genetics research.

Biotechnological innovation.

The critical issue is whether consumers were properly informed that their genetic information could be used for commercial research.

D. Exclusivity through contractual restrictions

A company may impose contractual conditions prohibiting consumers from transferring their genomic results to competing laboratories.

Other restrictions may prevent researchers from independently analysing consumer-provided genetic information.

Such restrictions should be examined for fairness, proportionality, legitimate business justification, and potential anti-competitive effects.

E. Exclusivity through technological lock-in

Genomics companies may create proprietary testing platforms, software, data formats, and interpretation systems.

Consumers may find it difficult to transfer their information to another provider.

This can create:

High switching costs.

Dependence on one testing company.

Reduced consumer choice.

Barriers to entry for competing laboratories.

Long-term commercial control over genomic information.

4. Consumer Rights and Genomic Data Ownership

An important legal distinction exists between ownership of physical biological samples, rights concerning personal information, and intellectual-property rights in scientific inventions.

A. Right to informed consent

Consumers should understand:

What genetic information is collected.

Why the information is collected.

Whether the information will be shared.

Whether pharmaceutical companies can access it.

Whether it will be used for commercial research.

Whether it will be transferred internationally.

How long it will be retained.

Under Articles 4 and 5 of Moroccan Law No. 09-08, consent and transparency are important requirements for lawful processing.

B. Right to access genetic information

Article 7 provides individuals with a right to obtain information concerning the processing of their personal data, including relevant information about the data and its origin.

A genomics company should not treat its commercial database rights as eliminating the consumer's statutory access rights.

C. Right to correction

Genetic testing results may contain interpretation errors, incomplete information, or outdated risk assessments.

Individuals should be able to seek correction of inaccurate personal information where legally appropriate.

D. Confidentiality and security

Articles 23 and 24 of Law No. 09-08 establish important security and confidentiality obligations.

Companies handling genomic information should implement:

Encryption.

Access controls.

Secure storage.

Employee confidentiality obligations.

Audit mechanisms.

Restrictions on unauthorised disclosure.

Appropriate security arrangements with service providers.

E. Restrictions on secondary use

A consumer may initially provide DNA information for ancestry testing.

The company may subsequently wish to use the same information for pharmaceutical research.

This is a separate legal question.

Under Moroccan law, genetic information is expressly classified as sensitive personal data. Article 12 establishes prior authorisation requirements for relevant sensitive-data processing and genetic-data processing, subject to specified exceptions. Article 21 addresses the conditions for authorising sensitive-data processing.

Consequently, an ancestry-testing agreement should not automatically be interpreted as permission for unlimited pharmaceutical or commercial research.

bdj.mmsp.gov.ma+2

5. Competition Law Issues in Consumer Genomics Data Exclusivity

Consumer genomics data exclusivity can become a competition-law issue when control over genetic datasets gives a company the ability to exclude competitors or restrict innovation.

A. Abuse of dominant position

A genomics company controlling a particularly valuable genetic database may acquire substantial market power.

Potential abusive practices include:

Refusing reasonable access to essential datasets.

Imposing discriminatory licensing conditions.

Restricting competing testing laboratories.

Charging exclusionary licensing fees.

Preventing interoperability.

Using exclusive agreements to foreclose competing services.

Dominance alone is not unlawful. The relevant issue is whether conduct constitutes an abuse under applicable competition legislation.

B. Exclusive agreements with hospitals

Suppose a genomics company enters into an exclusive agreement with major Moroccan hospitals.

Under the agreement, hospitals must send all consumer genetic tests to that company.

Potential consequences include:

Reduced competition between laboratories.

Higher testing prices.

Reduced consumer choice.

Exclusion of smaller laboratories.

Dependence on a single service provider.

The arrangement should be assessed according to its market coverage, duration, competitive effects, and legitimate efficiency justifications.

C. Data concentration through mergers

A pharmaceutical company may acquire a genomics platform to obtain access to a large genetic database.

The acquisition could create competitive advantages in drug development and personalised medicine.

Moroccan merger-control authorities should examine whether the transaction could significantly restrict competition, including through control over strategically important datasets.

D. Refusal to license genomic databases

A company may refuse to license its proprietary database to another biotechnology business.

However, refusal to license is not automatically unlawful.

The analysis should consider:

Whether the company has a dominant position.

Whether the dataset is genuinely indispensable.

Whether effective competition can realistically exist without access.

Whether the refusal eliminates effective competition.

Whether there is an objective justification.

E. Consumer data portability and competition

Data portability can reduce switching costs and encourage competition.

For example, consumers should be able to obtain their genetic reports in an intelligible, transferable format, subject to appropriate identity verification, security, and legal restrictions.

This can promote independent analysis and competition between testing providers.

F. Protection of innovation

Competition law must also protect legitimate innovation incentives.

Companies investing in expensive genetic sequencing, laboratory infrastructure, and bioinformatics should be able to protect qualifying inventions, software, and original database structures.

The objective is to prevent abusive exclusion without eliminating legitimate intellectual-property protection.

6. Important Case Laws

Eight important comparative authorities

Important jurisdictional qualification: The following decisions are comparative authorities from the United States and European Union. They are not Moroccan judgments, and there is no established body of reported Moroccan case law specifically determining consumer genomics data exclusivity. Their principles can nevertheless help analyse analogous disputes under Moroccan law.

1. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), 569 U.S. 576

Facts: Myriad Genetics discovered the location and sequence of BRCA1 and BRCA2 genes and obtained patents relating to those genes.

The patents gave the company significant control over genetic testing involving the relevant sequences.

Judgment: The United States Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated. However, synthetically created complementary DNA (cDNA) may qualify for patent protection.

Legal principle: Naturally occurring genetic information cannot automatically become exclusive intellectual property merely because a company discovers or isolates it.

Relevance to Morocco: This decision supports the distinction between naturally occurring human genetic information and qualifying technological inventions. A Moroccan genomics company should not assume that discovering a genetic sequence gives it unrestricted ownership over the genetic information of individuals.

2. Moore v. Regents of the University of California (1990), 51 Cal. 3d 120

Facts: John Moore's biological samples were used by researchers to develop a commercially valuable cell line without his informed consent concerning the relevant commercial interests.

Judgment: The California Supreme Court rejected Moore's conversion claim over the excised cells but recognised the importance of informed consent and disclosure of researchers' personal and financial interests.

Legal principle: Commercial exploitation of biological material raises distinct issues of informed consent, disclosure, and the legal rights associated with research.

Relevance to Morocco: Genomics companies should disclose material commercial research interests when collecting biological samples. Consent to a medical procedure or genetic test should not automatically be treated as unrestricted permission for commercial exploitation.

3. Greenberg v. Miami Children's Hospital Research Institute (2003), 264 F. Supp. 2d 1064

Facts: Families affected by Canavan disease contributed biological samples and research assistance to support the identification of the disease-associated gene.

The researchers subsequently obtained intellectual-property protection over genetic discoveries and developed commercial testing arrangements.

Judgment: The court examined claims involving informed consent, unjust enrichment, fiduciary duties, and the alleged commercialisation of research contributions. Several claims were dismissed.

Legal principle: Genetic research involving contributions from patients and families raises serious questions about disclosure, research expectations, and commercialisation.

Relevance to Morocco: Companies collecting genetic information from consumers should clearly explain whether donated information will support commercial research and whether exclusive commercial arrangements may arise.

PubMed

4. Washington University v. Catalona (2007), 490 F.3d 667

Facts: Researchers and donors disputed ownership and control of biological samples collected for medical research.

Judgment: The United States Court of Appeals for the Eighth Circuit upheld the university's ownership and control of the research specimens under the circumstances of the case.

Legal principle: Ownership and control of biological research materials may depend on the terms of donation, institutional arrangements, and applicable law.

Relevance to Morocco: A genomics company or research institution should establish clear contractual terms concerning biological samples, genetic datasets, access, retention, and permissible research use. However, ownership of a sample does not automatically mean unrestricted ownership of the donor's personal genetic information.

5. Sorrell v. IMS Health Inc. (2011), 564 U.S. 552

Facts: Pharmaceutical data-mining companies purchased and analysed prescription information identifying individual doctors.

Vermont restricted the sale and use of such information for pharmaceutical marketing without the doctors' consent.

Judgment: The United States Supreme Court invalidated the challenged restrictions under the First Amendment because they imposed impermissible content- and speaker-based burdens on protected expression.

Legal principle: The commercial use and disclosure of sensitive information can create complex conflicts between privacy regulation, commercial activity, and constitutional rights.

Relevance to Morocco: Genomic data regulation should distinguish between legitimate privacy protections and unjustified commercial restrictions. This case does not establish a right to unrestricted commercial use of personal genetic data.

Justia U.S. Supreme Court Center+1

6. IMS Health GmbH & Co. OHG v. NDC Health GmbH & Co. KG (2004), Case C-418/01

Facts: IMS Health controlled a copyrighted regional sales-data structure used in the pharmaceutical industry. A competitor sought access to the structure to compete in the market.

Judgment: The Court of Justice of the European Union explained the exceptional circumstances in which a refusal to license intellectual property by a dominant undertaking may constitute an abuse.

The Court considered whether the input was indispensable, whether refusal would exclude competition in a secondary market, whether new products were prevented, and whether objective justification existed.

Legal principle: Intellectual-property exclusivity and competition law must be balanced. Refusal to license can be abusive in exceptional circumstances.

Relevance to Morocco: If a genomics company controls a dataset indispensable for competing genetic-testing services, its refusal to provide access may require competition-law scrutiny. The strict conditions for exceptional compulsory licensing must still be satisfied.

EUR-Lex

7. Radio Telefis Eireann v. Commission (Magill) (1995), Joined Cases C-241/91 P and C-242/91 P

Facts: Television broadcasters controlled copyright-protected programme information and refused to license it to a publisher seeking to produce comprehensive television guides.

Judgment: The European Court of Justice upheld the finding that the broadcasters' refusal could constitute an abuse of dominant position in exceptional circumstances.

Legal principle: Intellectual-property rights cannot invariably be used to prevent all meaningful competition in related markets.

Relevance to Morocco: A genomics database owner should not use exclusive rights to eliminate competing services where the strict exceptional conditions for an abuse of dominance are established.

8. Microsoft Corp. v. Commission (2007), Case T-201/04

Facts: Microsoft refused to provide interoperability information required by competing server-software developers.

Judgment: The General Court upheld the Commission's finding of abuse of dominance concerning Microsoft's refusal to supply interoperability information, subject to the conditions examined in the case.

Legal principle: Control over strategically important technological information can create barriers to competition when access is unreasonably withheld.

Relevance to Morocco: A genomics company controlling proprietary formats, testing interfaces, and genetic interpretation systems may create artificial switching barriers. Competition analysis should examine whether interoperability restrictions protect legitimate innovation or improperly exclude competitors.

7. Practical Legal Problems in Morocco

The following hypothetical situations demonstrate how consumer genomics exclusivity may create legal disputes.

8. Liability of Consumer Genomics Companies

A. Civil liability

A genomics company may face civil liability where unlawful processing, contractual misconduct, confidentiality breaches, or negligent security causes legally recognised harm.

Potential claims include:

Breach of contractual obligations.

Unlawful disclosure of personal information.

Failure to protect confidential information.

Misrepresentation of commercial data practices.

Negligent handling of biological samples.

B. Regulatory liability

Under Law No. 09-08, violations can result in regulatory and criminal consequences, depending on the conduct and applicable statutory provisions.

The CNDP may exercise its statutory supervisory powers.

C. Competition liability

Under Law No. 104-12, qualifying anti-competitive agreements and abuses of dominant position may attract enforcement action and statutory sanctions.

D. Intellectual-property liability

A company may face intellectual-property disputes involving:

Unauthorised database extraction.

Copyright infringement.

Patent infringement.

Unlawful use of proprietary software.

Breach of confidential commercial information.

However, intellectual-property protection does not override applicable personal-data protection requirements.

9. Recommended Regulatory Framework for Morocco

Morocco could strengthen the governance of consumer genomics data exclusivity through the following measures.

1. Specific genomic consent requirements

Require separate, understandable consent for genetic testing, commercial research, pharmaceutical partnerships, and other materially different uses.

2. Genetic data portability

Establish practical mechanisms for consumers to obtain and transfer their genetic information securely.

3. Restrictions on exclusive commercial licensing

Require closer scrutiny of exclusive agreements involving large or strategically important genomic databases.

4. Independent regulatory oversight

Strengthen coordination between the CNDP, competition authorities, health regulators, and relevant research institutions.

5. Protection against genetic discrimination

Develop safeguards against inappropriate use of genomic information in insurance, employment, lending, and other decisions.

6. Transparency in pharmaceutical partnerships

Require companies to explain whether genetic information will be used for drug development, commercial research, or licensing arrangements.

7. Data deletion and retention safeguards

Establish transparent retention periods and appropriate deletion mechanisms, subject to legitimate legal, medical, and research obligations.

8. Cross-border transfer protection

Ensure that international storage, processing, and transfer of Moroccan consumers' genetic information comply with applicable requirements of Law No. 09-08.

10. Critical Legal Analysis

Consumer genomics data exclusivity creates a conflict between three important interests.

First: Individual privacy. Genetic information is uniquely sensitive because it can reveal hereditary conditions, family relationships, and biological characteristics.

Second: Commercial innovation. Genomics companies invest considerable resources in sequencing technology, analytical software, research infrastructure, and database development. Legitimate investment should receive appropriate legal protection.

Third: Market competition. Exclusive control over large genetic datasets may create competitive advantages that prevent smaller companies and independent researchers from developing alternative services.

The appropriate legal approach is therefore neither unlimited corporate ownership nor compulsory unrestricted access to every genomic database.

Instead, the law should distinguish between:

Individual genetic information.

Physical biological samples.

Anonymised or aggregated datasets.

Original database structures.

Proprietary analytical algorithms.

Patentable technological inventions.

Confidential commercial research.

Each category requires a different legal analysis.

11. Conclusion

Consumer Genomics Data Exclusivity is an emerging legal issue at the intersection of data protection, biotechnology, consumer rights, intellectual property, and competition law.

In Morocco, Law No. 09-08 provides a particularly important foundation because it expressly recognises genetic information as sensitive personal data. Law No. 31-08 provides consumer-protection safeguards, while Law No. 17-97 and Law No. 104-12 are relevant to intellectual-property and competition disputes.

The comparative judgments in Myriad Genetics, Moore, Greenberg, Catalona, Sorrell, IMS Health, Magill, and Microsoft demonstrate that commercial control over genetic information, biological materials, and proprietary databases must be assessed against individual rights and legitimate competitive interests.

The central legal principle is that a genomics company may protect legitimate technological innovation and qualifying database rights, but commercial exclusivity should not become an unrestricted right to control, exploit, or monopolise an individual's genetic identity.

Research qualification: The eight judgments above are comparative case-law authorities, not eight Moroccan precedents. Their application in Morocco must be assessed under Moroccan legislation and judicial interpretation.